This Research Unit’s goal is to describe the DNA methylation pattern and how it affects the development of neurological diseases, especially degenerative dementias like Alzheimer’s disease. The ultimate goal is to find epigenetic biomarkers that could be used for diagnosis, prognosis and treatment. Research in this field covers other neurological disorders such as epilepsy or multiple sclerosis. The Unit is particularly interested in epigenetic modifications in certain rare monogenic disorders associated with neurological disorders like laminopathies.
The team work in cooperation with other teams from the Navarra Hospital Complex. They study stroke biomarkers along with the Vascular Brain Disease Group, the Neuromuscular Disease and Motor Brain Cell Group and the Multiple Sclerosis Group. Additionally, they aim at describing how environmental factors or targeted activities affect methylation patterns in healthy individuals.
Lines of research:
- Identification of epigenetic biomarkers in Alzheimer’s and other neurodegenerative diseases.
- Neurogenesis mechanisms in Alzheimer’s disease: new therapeutic targets.
- Epigenetic regulation in laminopathies and other rare diseases.
- Meditation-induced epigenetic modifications.
Navarrabiomed - Centro de investigación biomédica
Complejo Hospitalario de Navarra, edificio de investigación.
Calle Irunlarrea, 3. 31008 Pamplona, Navarra, España.